Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All aspirin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 27% Improvement Relative Risk Mortality (b) 14% Aspirin for COVID-19  Al Harthi et al.  LATE TREATMENT Is late treatment with aspirin beneficial for COVID-19? PSM retrospective 351 patients in Saudi Arabia Lower mortality with aspirin (p=0.03) c19early.org Al Harthi et al., J. Intensive Care Me.., Sep 2021 Favors aspirin Favors control

Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study

Al Harthi et al., Journal of Intensive Care Medicine, doi:10.1177/08850666221093229
Sep 2021  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 1,033 critical condition patients, showing lower in-hospital mortality with aspirin in PSM analysis. Patients receiving aspirin also had a higher risk of significant bleeding, although not reaching statistical significance. Authors note that the use of aspirin during an ICU stay should be tailored to each patient.
risk of death, 27.0% lower, HR 0.73, p = 0.03, treatment 98 of 176 (55.7%), control 107 of 173 (61.8%), adjusted per study, in-hospital mortality, multivariable Cox proportional hazards.
risk of death, 14.0% lower, HR 0.86, p = 0.30, treatment 95 of 176 (54.0%), control 97 of 175 (55.4%), adjusted per study, day 30, multivariable Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Al Harthi et al., 3 Sep 2021, retrospective, propensity score matching, Saudi Arabia, peer-reviewed, 21 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Evaluation of low-dose aspirin use among COVID-19 critically ill patients: A Multicenter Propensity Score Matched Study
Abdullah Al Harthi, Khalid Al Sulaiman, Ohoud Aljuhani, Ghazwa B Korayem, Ali F Altebainawi, Raghdah S Alenezi, Shmeylan Al Harbi, Jawaher Gramish, Raed Kensara, Awattif Hafidh, Huda Al Enazi, Ahad Alawad, Rand Alotaibi, Abdulaziz Alshehri, Omar Alhuthaili, Ramesh Vishwakarma, Khalid Bin Saleh, Thamer Alsulaiman, Rahaf Ali Alqahtani, Saja Almazrou, Sajid Hussain
doi:10.21203/rs.3.rs-872891/v1
Background Multiple medications with anti-in ammatory effects have been used to manage the hyper-in ammatory response associated with COVID-19. Aspirin is used widely as a cardioprotective agent due to its antiplatelet and anti-in ammatory properties. Its role in hospitalized COVID-19 patients has been assessed and evaluated in the literature. However, no data regards its role in COVID-19 critically ill patients. Therefore, this study aims to evaluate the use of low-dose aspirin (81-100 mg) and its impact on outcomes in COVID-19 critically ill patients. Method This is a multicenter, retrospective cohort study for all adult critically ill patients with con rmed COVID-19 admitted to Intensive Care Units (ICUs) between March 1, 2020, and March 31, 2021. Eligible patients were classi ed into two groups based on aspirin use during ICU stay. The primary outcome is the in-hospital mortality; other outcomes were considered secondary. Propensity score-matched used based on patient's age, SOFA score, MV status within 24 hours of ICU admission, prone position status, ischemic heart disease (IHD), and stroke as co-existing illness. We considered a P value of < 0.05 statistically signi cant. Results A total of 1033 patients were eligible; 352 patients were included after propensity score matching (1:1 ratio). The in-hospital mortality (HR (95%CI): 0.73 (0.56, 0.97), p-value=0.03) were lower in patients who received aspirin during hospital stay. On the other hand, patients who received aspirin have a higher risk of major bleeding compared to the control group (OR (95%CI): 2.92 (0.91, 9.36), p-value=0.07); but was not statistically signi cant. Conclusion Aspirin use in COVID-19 critically ill patients may have a mortality bene t; nevertheless, it may be linked with an increased risk of signi cant bleeding. The bene t-risk evaluation for aspirin usage during an ICU stay should be tailored to each patient.
Author contributions All authors contributed to data collections, analysis, drafted, revised, and approved the nal version of the manuscript. Funding None. Ethics approval and consent to participate The study was approved in March 2021 by King Abdullah International Medical Research Center Institutional Review Board, Riyadh, Saudi Arabia (Ref.# NRC21R/058/02). Participants' con dentiality was strictly observed throughout the study by using anonymous unique serial number for each subject and restricting data only to the investigators. Informed consent was not required due to the research's method as per the policy of the governmental and local research center. Consent for publication Not applicable. Competing interests No author has a con ict of interest in this study.
References
Aghajani, Moradi, Amini, Tehrani, Pourheidar et al., Decreased inhospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19, J Med Virol, doi:10.1002/jmv.27053
Ahmed, Merrell, Ismail, Joudeh, Riley et al., Rationales and uncertainties for aspirin use in COVID-19: a narrative review, Fam Med community Heal
Berardis, Lucisano, 'ettorre, Pellegrini, Lepore et al., Association of aspirin use with major bleeding in patients with and without diabetes, JAMA
Chernysh, Nagaswami, Kosolapova, Peshkova, Cuker et al., Con rmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis, Thromb Res, doi:10.1038/s41598-020-59526-x
Chow, Khanna, Kethireddy, Yamane, Levine et al., Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019, Anesth Analg
Cook, Fuller, Guyatt, Marshall, Leasa et al., Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group, N Engl J Med
Goligher, Bradbury, Mcverry, Lawler, Berger et al., Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19, N Engl J Med
Group, Horby, Pessoa-Amorim, Staplin, Emberson et al., COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Hayakawa, Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments, Open Access Emerg Med
Hottz, Azevedo-Quintanilha, Palhinha, Teixeira, Barreto et al., Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19, Blood, doi:10.1182/blood.2020007252
Johnson, Department, Surgery, St, Catholic et al., The Novel Aspirin as Breakthrough Drug for COVID-19: A Narrative Review, Iberoam J Med
Lauzier, Arnold, Rabbat, Heels-Ansdell, Zarychanski et al., Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis, Intensive Care Med
Lin, Chen, Acute kidney injury classi cation: AKIN and RIFLE criteria in critical patients, World J Crit care Med
Mcneil, Wolfe, Woods, Tonkin, Donnan et al., Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly, N Engl J Med
Meizlish, Goshua, Liu, Fine, Amin et al., Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis, medRxiv
Osborne, Veigulis, Arreola, Mahajan, Röösli et al., Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration, PLoS One
Rodriguez-Roisin, Pulmonary gas exchange in acute respiratory failure, Eur J Anaesthesiol
Sadeghipour, Talasaz, Rashidi, Sharif-Kashani, Beigmohammadi et al., Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial, JAMA
Sahai, Bhandari, Godwin, Mcintyre, Chung et al., Effect of aspirin on shortterm outcomes in hospitalized patients with COVID-19, Vasc Med, doi:10.1177/1358863X211012754
Saleh K Bin, Ha Z A, Alsulaiman, Aljuhani, Alharbi, Alharbi, Clinical characteristics and outcomes of patients with heart failure admitted to the intensive care unit with coronavirus disease 2019 (COVID-19): A multicenter cohort study, Am Hear J plus Cardiol Res Pract
Schulman, Kearon, De nition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, J Thromb Haemost
Wu, Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, JAMA
Xu, Zhou, Xu, Mechanism of thrombocytopenia in COVID-19 patients, Ann Hematol, doi:10.1007/s00277-020-04019-0
Yuan, Chen, Li, Chen, Wang et al., Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease, J Cell Mol Med, doi:10.1111/jcmm.16198
Zhang, Cao, Jiang, Xiao, Li et al., Pro le of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients, J Thromb Thrombolysis, doi:10.1007/s11239-020-02182-9
Zheng, Roddick, Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis, JAMA
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit